학술논문
Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma
Document Type
article
Author
Gyurdieva, Alexandra; Zajic, Stefan; Chang, Ya-Fang; Houseman, E Andres; Zhong, Shan; Kim, Jaegil; Nathenson, Michael; Faitg, Thomas; Woessner, Mary; Turner, David C; Hasan, Aisha N; Glod, John; Kaplan, Rosandra N; D’Angelo, Sandra P; Araujo, Dejka M; Chow, Warren A; Druta, Mihaela; Demetri, George D; Van Tine, Brian A; Grupp, Stephan A; Fine, Gregg D; Eleftheriadou, Ioanna
Source
Nature Communications. 13(1)
Subject
Language
Abstract
Autologous T cells transduced to express a high affinity T-cell receptor specific to NY-ESO-1 (letetresgene autoleucel, lete-cel) show promise in the treatment of metastatic synovial sarcoma, with 50% overall response rate. The efficacy of lete-cel treatment in 45 synovial sarcoma patients (NCT01343043) has been previously reported, however, biomarkers predictive of response and resistance remain to be better defined. This post-hoc analysis identifies associations of response to lete-cel with lymphodepleting chemotherapy regimen (LDR), product attributes, cell expansion, cytokines, and tumor gene expression. Responders have higher IL-15 levels pre-infusion (p = 0.011) and receive a higher number of transduced effector memory (CD45RA- CCR7-) CD8 + cells per kg (p = 0.039). Post-infusion, responders have increased IFNγ, IL-6, and peak cell expansion (p